Ajinomoto and Olon collaborate on peptide manufacturing

Ajinomoto Bio-Pharma Services (Aji Bio-Pharma) and Olon S.p.A. are teaming up. This partnership seeks to change how we make large-scale peptides and proteins. Together, they drive innovation in biopharmaceutical production.

This partnership merges Aji Bio-Pharma’s CORYNEX® platform, known for producing soluble, active proteins, with Olon’s robust GMP fermentation expertise. Olon uses bioreactors that hold more than 100,000 liters. These companies will boost the green production of key therapeutic compounds. This includes GLP-1 analogs. They are effective for treating obesity and Type II diabetes.

CORYNEX® comes from the gram-positive bacterium Corynebacterium glutamicum. This bacterium is a strong microbial platform. It makes bioprocessing easy. Active proteins are secreted directly into the culture media. This process doesn’t need chemical inducers. Olon has strong skills in high-containment microbial fermentation. It also has one of Europe’s largest total capacities at 5,000 m³.

Also Read: Amato Pharmaceutical Boosts Data Accuracy with Ecforce

The partnership brings together scalable microbial technology and extensive infrastructure. This plan speeds up development times and boosts yield efficiency. It also seeks to expand global peptide and protein supply chains for pharma and biotech clients.